Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atovaquone + azithromycin
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Atovaquone + azithromycin is a combination therapy primarily used for the treatment of babesiosis, a tick-borne parasitic infection. This regimen has been shown to be as effective as the alternative combination of clindamycin and quinine but is associated with significantly fewer adverse reactions. The combination works by targeting the Babesia parasites through different mechanisms, with atovaquone interfering with electron transport in parasite mitochondria and azithromycin inhibiting protein synthesis by binding to the 50S ribosomal subunit.
- Other names
- atovaquone and azithromycinatovaquone/azithromycin
02
Targets
60S (Eukaryotic 60S ribosomal subunit)bc1 complex (Cytochrome bc1 complex (plasmodium))ND1 (Mitochondrial electron transport chain complex I)
Beyond the preview
Go deeper on atovaquone + azithromycin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atovaquone + azithromycin.